A novel monoclonal antibody targeting carboxymethyllysine, an advanced glycation end product in atherosclerosis and pancreatic cancer
(2018) In PLoS ONE 13(2).- Abstract
Advanced glycation end products are formed by non-enzymatic reactions between proteins and carbohydrates, causing irreversible lysine and arginine alterations that severely affect protein structure and function. The resulting modifications induce inflammation by binding to scavenger receptors. An increase in advanced glycation end products is observed in a number of diseases e.g. atherosclerosis and cancer. Since advanced glycation end products also are present in healthy individuals, their detection and quantification are of great importance for usage as potential biomarkers. Current methods for advanced glycation end product detection are though limited and solely measure total glycation. This study describes a new epitope-mapped... (More)
Advanced glycation end products are formed by non-enzymatic reactions between proteins and carbohydrates, causing irreversible lysine and arginine alterations that severely affect protein structure and function. The resulting modifications induce inflammation by binding to scavenger receptors. An increase in advanced glycation end products is observed in a number of diseases e.g. atherosclerosis and cancer. Since advanced glycation end products also are present in healthy individuals, their detection and quantification are of great importance for usage as potential biomarkers. Current methods for advanced glycation end product detection are though limited and solely measure total glycation. This study describes a new epitope-mapped single chain variable fragment, D1-B2, against carboxymethyllysine, produced from a phage library that was constructed from mouse immunizations. The phage library was selected against advanced glycation end product targets using a phage display platform. Characterization of its binding pattern was performed using large synthetic glycated peptide and protein libraries displayed on microarray slides. D1-B2 showed a preference for an aspartic acid, three positions N-terminally from a carboxymethyllysine residue and also bound to a broad collection of glycated proteins. Positive immunohistochemical staining of mouse atherosclerotic plaques and of a tissue microarray of human pancreatic tumors confirmed the usability of the new scFv for advanced glycation end product detection in tissues. This study demonstrates a promising methodology for high-throughput generation of epitope-mapped monoclonal antibodies against AGE.
(Less)
- author
- Wendel, Ulrika ; Persson, Nina ; Risinger, Christian ; Bengtsson, Eva LU ; Nodin, Björn LU ; Danielsson, Lena LU ; Welinder, Charlotte LU ; Fredrikson, Gunilla Nordin LU ; Jansson, Bo LU and Blixt, Ola
- organization
-
- EXODIAB: Excellence of Diabetes Research in Sweden
- Department of Experimental Medical Science
- Personalized Pathology & Cancer Therapy (research group)
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- Protease Inhibitor Research (research group)
- CEBMMS PI (research group)
- Cardiovascular Research - Immunity and Atherosclerosis (research group)
- Tumor microenvironment
- publishing date
- 2018-02-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- PLoS ONE
- volume
- 13
- issue
- 2
- article number
- e0191872
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- pmid:29420566
- scopus:85041959941
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0191872
- language
- English
- LU publication?
- yes
- id
- 5f2f0888-7f53-4075-8059-83165c6b2f52
- date added to LUP
- 2018-02-21 10:28:06
- date last changed
- 2024-08-19 13:40:56
@article{5f2f0888-7f53-4075-8059-83165c6b2f52, abstract = {{<p>Advanced glycation end products are formed by non-enzymatic reactions between proteins and carbohydrates, causing irreversible lysine and arginine alterations that severely affect protein structure and function. The resulting modifications induce inflammation by binding to scavenger receptors. An increase in advanced glycation end products is observed in a number of diseases e.g. atherosclerosis and cancer. Since advanced glycation end products also are present in healthy individuals, their detection and quantification are of great importance for usage as potential biomarkers. Current methods for advanced glycation end product detection are though limited and solely measure total glycation. This study describes a new epitope-mapped single chain variable fragment, D1-B2, against carboxymethyllysine, produced from a phage library that was constructed from mouse immunizations. The phage library was selected against advanced glycation end product targets using a phage display platform. Characterization of its binding pattern was performed using large synthetic glycated peptide and protein libraries displayed on microarray slides. D1-B2 showed a preference for an aspartic acid, three positions N-terminally from a carboxymethyllysine residue and also bound to a broad collection of glycated proteins. Positive immunohistochemical staining of mouse atherosclerotic plaques and of a tissue microarray of human pancreatic tumors confirmed the usability of the new scFv for advanced glycation end product detection in tissues. This study demonstrates a promising methodology for high-throughput generation of epitope-mapped monoclonal antibodies against AGE.</p>}}, author = {{Wendel, Ulrika and Persson, Nina and Risinger, Christian and Bengtsson, Eva and Nodin, Björn and Danielsson, Lena and Welinder, Charlotte and Fredrikson, Gunilla Nordin and Jansson, Bo and Blixt, Ola}}, issn = {{1932-6203}}, language = {{eng}}, month = {{02}}, number = {{2}}, publisher = {{Public Library of Science (PLoS)}}, series = {{PLoS ONE}}, title = {{A novel monoclonal antibody targeting carboxymethyllysine, an advanced glycation end product in atherosclerosis and pancreatic cancer}}, url = {{http://dx.doi.org/10.1371/journal.pone.0191872}}, doi = {{10.1371/journal.pone.0191872}}, volume = {{13}}, year = {{2018}}, }